E Fund Management’s Akebia Therapeutics AKBA Stock Holding History

E Fund Management’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$57.2K	Buy	+41,119	New	+$56.5K	﹤0.01%	486
2025 Q2	$103K	Buy	28,273 +8,962	+46%	+$24.6K	﹤0.01%	375
2025 Q1	$37.1K	Buy	19,311 +6,595	+52%	+$13.5K	﹤0.01%	395
2024 Q4	$24.2K	Buy	+12,716	New	+$22.1K	﹤0.01%	394
2022 Q2	–	Sell	-35,250	Closed	-$25K	–	324
2022 Q1	$25K	Buy	35,250 +10,853	+44%	+$23.2K	﹤0.01%	325
2021 Q4	$55K	Sell	24,397 -12,726	-34%	-$34.7K	﹤0.01%	296
2021 Q3	$107K	Buy	+37,123	New	+$106K	﹤0.01%	258
2021 Q1	$130K	Buy	+38,410	New	+$138K	0.01%	229

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

E Fund Management's AKBA Position: Q1 2026 in Review

E Fund Management opened a new position in Akebia Therapeutics (AKBA) in Q1 2026: 41,119 shares worth $57.2K. The stake represents ﹤0.01% of the portfolio and ranks #486 among its holdings. This is a return to the name: E Fund Management previously reported a position in AKBA as recently as Q2 2025.

E Fund Management first reported a position in AKBA in Q1 2021 and has held it in 8 quarters since. The position peaked at $130K in Q1 2021. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

E Fund Management held 41,119 shares of Akebia Therapeutics worth $57.2K as of Q1 2026.
Akebia Therapeutics was a new E Fund Management position in Q1 2026.
Akebia Therapeutics made up ﹤0.01% of E Fund Management's portfolio in Q1 2026, its #486 holding.
E Fund Management first reported a position in Akebia Therapeutics in Q1 2021 and has held it in 8 quarters since.
E Fund Management's Akebia Therapeutics position peaked at $130K in Q1 2021.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on E Fund Management's 13F filing for Q1 2026, filed 13 Apr 2026.